|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Mann_Kind_Corporation
|
|
gptkbp:approves
|
FDA approved products
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:business_model
|
biopharmaceuticals
|
|
gptkbp:ceo
|
gptkb:Michael_A._Castagna
|
|
gptkbp:clinical_trial
|
gptkb:Afrezza
Phase 2 and Phase 3
ongoing studies
Phase 3 trials for Afrezza
|
|
gptkbp:collaborations
|
research institutions
|
|
gptkbp:community_engagement
|
healthcare initiatives
|
|
gptkbp:conflict
|
competition in diabetes care
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:financial_performance
|
quarterly and annual reports available
|
|
gptkbp:financial_products
|
publicly traded
|
|
gptkbp:focus
|
diabetes treatment
|
|
gptkbp:founded
|
gptkb:2001
|
|
gptkbp:founder
|
gptkb:Alfred_Mann
|
|
gptkbp:future_plans
|
expand product offerings
|
|
gptkbp:governed_by
|
expanding market presence
|
|
gptkbp:headquarters
|
gptkb:Valencia,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MNKD
|
|
gptkbp:industry
|
gptkb:Company
|
|
gptkbp:innovation
|
focus on inhaled insulin delivery
|
|
gptkbp:invention
|
multiple patents for inhaled insulin
|
|
gptkbp:investment
|
available online
various venture capital firms
available on website
diabetes management
volatile
in R& D
|
|
gptkbp:key_people
|
gptkb:Alfred_Mann
|
|
gptkbp:language_of_instruction
|
multiple products in development
|
|
gptkbp:market
|
Afrezza in 2014
|
|
gptkbp:market_cap
|
approximately $300 million
|
|
gptkbp:marketing_strategy
|
focus on inhaled therapies
|
|
gptkbp:partnership
|
gptkb:Sanofi
gptkb:United_Therapeutics
|
|
gptkbp:partnerships
|
various healthcare companies
|
|
gptkbp:products
|
gptkb:Afrezza
inhalation technology
|
|
gptkbp:regulatory_compliance
|
FDA approval for Afrezza
|
|
gptkbp:research
|
gptkb:David_A._Kessler
|
|
gptkbp:research_and_development
|
insulin delivery systems
|
|
gptkbp:research_focus
|
diabetes and metabolic disorders
|
|
gptkbp:revenue
|
$20 million (2020)
|
|
gptkbp:social_responsibility
|
healthcare access initiatives
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
public since 2014
|
|
gptkbp:subsidiary
|
gptkb:Mann_Kind_Corporation
|
|
gptkbp:supply_chain
|
global suppliers
|
|
gptkbp:symbol
|
gptkb:MNKD
|
|
gptkbp:team
|
experienced executives
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:treatment
|
improved diabetes management
|
|
gptkbp:website
|
www.mannkindcorp.com
|
|
gptkbp:bfsParent
|
gptkb:Mann_Kind_Corporation
|
|
gptkbp:bfsLayer
|
5
|